市場調查報告書

脊髓小腦失調症(SCA)- 市場洞察,流行病學,市場預測 2028年

Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 773932
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
脊髓小腦失調症(SCA)- 市場洞察,流行病學,市場預測 2028年 Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年09月01日內容資訊: 英文 118 Pages
簡介

主要7個國家的脊髓小腦失調症(SCA)的患病數在2017年估算為42,043人,以及市場規模推算為3,020萬美元。

提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的脊髓小腦失調症(SCA)的流行病學的相關調查,疾病及市場概要,整體及各國患病數及診斷數的變化與預測,未滿足需求,新藥及候補藥概要,各國市場規模,市場成長要素及障礙等相關資訊。

目錄

第1章 重要洞察

第2章 脊髓小腦失調症(SCA)市場概要

  • 市場佔有率與分佈情形(實際成果值)
  • 市場佔有率與分佈情形(預測值)

第3章 疾病的背景和概要

  • 簡介
  • 脊髓小腦失調症(SCA):各病型
    • 脊髓小腦失調症第一型(SCA1)
    • 脊髓小腦失調症2型(SCA2)
    • 脊髓小腦失調症3型(SCA3)
    • 脊髓小腦失調症6型(SCA6)
    • 脊髓小腦失調症7型(SCA7)
  • 原因和危險因素
  • 歷史
  • 徵兆與症狀
  • 病理生理學
  • 診斷
  • 生物標記
    • 神經成像生物標記物
    • 眼球運動生物標記
    • 生物學性生物標記

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的脊髓小腦失調症(SCA)的患病數

第5章 脊髓小腦失調症(SCA)的流行病學分析:各國

  • 美國
    • 假設和根據
    • 總患病數
    • 總診斷數
    • 診斷數:各病型
  • 歐洲5個國家
    • 德國
      • 總患病數
      • 總診斷數
      • 診斷數:各病型
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 治療方法

  • 潛在性治療方法
  • 美國的指南
  • 歐洲的指南
  • 脊髓小腦失調症(SCA)的管理

第7章 未滿足需求

第8章 新藥

  • Troriluzole:Biohaven Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Rovatirelin (KPS-0373): Kissei藥品工業

第9章 其他有潛力候補藥

  • IB1001:IntraBio
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 產品簡介
  • Stemchymal:Steminent Biotherapeutics

第10章 市場分析脊髓小腦失調症(SCA):主要7個國家

  • 主要調查結果
  • 主要7個國家的市場規模

第11章 美國市場預測

  • 美國的市場規模
    • 總市場規模
    • 市場規模:各選擇藥

第12章 市場預測歐洲5個國家

  • 德國
    • 總市場規模
    • 市場規模:各選擇藥
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

  • 報告方法

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0470

DelveInsight's 'Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SCA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Spinocerebellar Ataxia (SCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Spinocerebellar Ataxia (SCA) - Disease Understanding and Treatment Algorithm

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

The DelveInsight Spinocerebellar Ataxia (SCA) market report gives the thorough understanding of the Spinocerebellar Ataxia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Spinocerebellar Ataxia in the US, Europe and Japan.

Spinocerebellar Ataxia Epidemiology

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Spinocerebellar Ataxia Drug Chapters

This segment of the Spinocerebellar Ataxia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The SCA market forecast provided in the report solely focuses on the market revenue generated by the pharmacological treatment (including off-label symptomatic therapies, such as Neuro-protective agents, Nicotine Receptor Agonists, Serotonergic Therapy, and GABAergic Therapy) used for SCA management in the diagnosed cases. Detailed chapter for upcoming therapies like Troriluzole (BHV-4157; Biohaven Pharmaceuticals) and KPS-0373 (Rovatirelin; Kissei Pharmaceuticals) have been covered in the report.

Spinocerebellar Ataxia Market Outlook

The Spinocerebellar Ataxia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Spinocerebellar Ataxia in 7MM was found to be USD 30.28 Million in 2017, and is expected to further increase during the course of the study period from 2017-2028. Among the 7MM, Japan accounts for the largest market size of Spinocerebellar Ataxia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and the United States.

Spinocerebellar Ataxia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Spinocerebellar Ataxia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Spinocerebellar Ataxia Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Spinocerebellar Ataxia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Spinocerebellar Ataxia market
  • Organize sales and marketing efforts by identifying the best opportunities for Spinocerebellar Ataxia market
  • To understand the future market competition in the Spinocerebellar Ataxia market.

Table of Contents

1. Key Insights

2. Spinocerebellar Ataxia Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Spinocerebellar Ataxia in 2017
  • 2.2. Market Share (%) Distribution of Spinocerebellar Ataxia in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes of SCA
    • 3.2.1. SCA1
    • 3.2.2. SCA2
    • 3.2.3. SCA3
    • 3.2.4. SCA6
    • 3.2.5. SCA7
  • 3.3. Causes and risk factors
  • 3.4. History
  • 3.5. Signs and Symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
  • 3.8. Biomarkers
    • 3.8.1. Neuroimaging biomarkers
    • 3.8.2. Oculomotor biomarkers
    • 3.8.3. Biological biomarkers

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Patient Population of Spinocerebellar Ataxia

5. Country Wise-Epidemiology of Spinocerebellar Ataxia

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
    • 5.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
    • 5.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
    • 5.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
    • 5.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
  • 5.4. France
    • 5.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
    • 5.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
    • 5.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
  • 5.5. Italy
    • 5.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
    • 5.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
    • 5.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
  • 5.6. Spain
    • 5.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
    • 5.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
    • 5.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
  • 5.7. United Kingdom
    • 5.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
    • 5.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
    • 5.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
    • 5.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
    • 5.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

6. Treatments

  • 6.1. Potential treatments
  • 6.2. U.S. Guidelines
    • 6.2.1. Local Susceptibility of Host Tissue
  • 6.3. Europe Guidelines
  • 6.4. Management of Spinocerebellar Ataxia

7. Unmet Needs

8. Emerging Therapies

  • 8.1. Troriluzole: Biohaven Pharmaceuticals
    • 8.1.1. Product Description
    • 8.1.2. Other Development Activities
    • 8.1.3. Clinical Development
    • 8.1.4. Safety and Efficacy
    • 8.1.5. Product Profile
  • 8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical
    • 8.2.1. Product Description
    • 8.2.2. Clinical Development
    • 8.2.3. Safety and Efficacy
    • 8.2.4. Product Profile

9. Other Promising Candidates

  • 9.1. IB1001: IntraBio
    • 9.1.1. Product Description
    • 9.1.2. Other Development Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Product Profile
  • 9.2. Stemchymal: Steminent Biotherapeutics
    • 9.2.1. Product Description
    • 9.2.2. Other Development Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile

10. Spinocerebellar Ataxia: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Spinocerebellar Ataxia in 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market size of Spinocerebellar Ataxia
    • 11.1.2. Market Size by Line of Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of Spinocerebellar Ataxia in Germany
    • 12.1.2. Market Size by Line of Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Spinocerebellar Ataxia
    • 12.2.2. Market Size by Line of Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Spinocerebellar Ataxia
    • 12.3.2. Market Size by Line of Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Spinocerebellar Ataxia
    • 12.4.2. Market Size by Line of Therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Spinocerebellar Ataxia
    • 12.5.2. Market Size by Line of Therapies
  • 12.6. Japan: Market Outlook
  • 12.7. Japan Market Size
    • 12.7.1. Total Market Size of Spinocerebellar Ataxia
    • 12.7.2. Market Size by Line of Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1: SCA subtypes
  • Table 2: SCA subtypes with associated clinical signs
  • Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 25: Troriluzole ,Clinical Trial Description, 2019
  • Table 26: Rovatirelin ,Clinical Trial Description, 2019
  • Table 27: IB1001 ,Clinical Trial Description, 2019
  • Table 28: Stemchymal, Clinical Trial Description, 2019
  • Table 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028)
  • Table 30: United States Market Size of Spinocerebellar Ataxia in the US, USD Million (2017-2028)
  • Table 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028)
  • Table 32: Market Size of Spinocerebellar Ataxia in Germany, in USD Million (2017-2028)
  • Table 33: Market Size of Spinocerebellar Ataxia by Line of Therapies in Germany, in USD Million (2017-2028)
  • Table 34: Market Size of Spinocerebellar Ataxia in France, in USD Million (2017-2028)
  • Table 35: Market Size of Spinocerebellar Ataxia by Line of Therapies in France, in USD Million (2017-2028)
  • Table 36: Market Size of Spinocerebellar Ataxia in Italy, in USD Million (2017-2028)
  • Table 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028)
  • Table 38: Market Size of Spinocerebellar Ataxia in Spain, in USD Million (2017-2028)
  • Table 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028)
  • Table 40: Market Size of Spinocerebellar Ataxia in the UK, in USD Million (2017-2028)
  • Table 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028)
  • Table 42: Market Size of Spinocerebellar Ataxia in Japan, in USD, Million (2017-2028)
  • Table 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: SCA subtypes overall prevalence
  • Figure 2: Repeat expansions that cause ataxia
  • Figure 3: Harding's classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation
  • Figure 4: Common disease mechanisms underlying SCAs.
  • Figure 5: Flowchart of molecular genetic diagnosis of SCAs
  • Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 12:Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 18:Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 27:Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 28: Unmet Needs of Spinocerebellar ataxia
  • Figure 29: 7 Major Market Size of Spinocerebellar Ataxia in USD Million (2017-2028)
  • Figure 30: Market Size of Spinocerebellar Ataxia in the United States, USD Millions (2017-2028)
  • Figure 31: Market Size of Spinocerebellar Ataxia by Line of Therapies in the US, in USD Million (2017-2028)
  • Figure 32: Market Size of Spinocerebellar Ataxia in Germany, USD Million (2017-2028)
  • Figure 33: Market Size of Spinocerebellar Ataxia by Line of Therapies, in Germany, in USD Million (2017-2028)
  • Figure 34: Market Size of Spinocerebellar Ataxia in France, USD Million (2017-2028)
  • Figure 35: Market Size of Spinocerebellar Ataxia by Line of Therapies, in France, in USD Million (2017-2028)
  • Figure 36: Market Size of Spinocerebellar Ataxia in Italy, USD Million (2017-2028)
  • Figure 37: Market Size of Spinocerebellar Ataxia by Line of Therapies in Italy, in USD Million (2017-2028)
  • Figure 38: Market Size of Spinocerebellar Ataxia in Spain, USD Million (2017-2028)
  • Figure 39: Market Size of Spinocerebellar Ataxia by Line of Therapies in Spain, in USD Million (2017-2028)
  • Figure 40: Market Size of Spinocerebellar Ataxia in the UK, USD Million (2017-2028)
  • Figure 41: Market Size of Spinocerebellar Ataxia by Line of Therapies in the UK, in USD Million (2017-2028)
  • Figure 42: Market Size of Spinocerebellar Ataxia in Japan, USD Million (2017-2028)
  • Figure 43: Market Size of Spinocerebellar Ataxia by Line of Therapies in Japan, in USD Million (2017-2028)
  • Figure 44: Market Drivers
  • Figure 45: Market Barriers
Back to Top